To probe into the application value of human immunoglobulin in the treatment of severe pneumonia in children requiring methylprednisolone ( methylprednisolone sodium succinate for injection). Methods: Clinical data of children with severe pneumonia hospitalized in our hospital from Jan. 2021 to Jun. 2022 were retrospectively analyzed. Forty-four children who received methylprednisolone but no human immunoglobulin as adjuvant therapy were selected as the control group

and 47 children who received methylprednisolone and human immunoglobulin as adjuvant therapy were selected as the observation group. The improvement time of clinical symptom

imaging before and after treatment

test results

efficacy and adverse drug reactions of two groups were analyzed. Results: The total effective rate of the observation group ( 91. 49%) was higher than that of the control group ( 70. 45%). The improvement time of clinical symptoms in the observation group was shorter than that of the control group. The proportion of children with lung shadow absorption ≥80% was higher than that of control group after 2 weeks of treatment. The reduction of C-reactive protein (CRP)

white blood cell (WBC) count and procalcitonin (PCT) in the observation group was greater than that in control group (P< 0. 05). No adverse drug reactions occurred in two groups. Conclusion:The application of human immunoglobulin in children with severe pneumonia with methylprednisolone as adjuvant treatment is safe and feasible

which can effectively improve the clinical efficacy. Considering that intravenous human immunoglobulin is the blood product with high cost and medication risk

it is recommended that the clinicians should use human immunoglobulin strictly according to the indications after full communication with family members of patients.